Insmed Inc (INSM)vsOculis Holding AG Ordinary shares (OCS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
OCS
Oculis Holding AG Ordinary shares
$25.00
+1.96%
HEALTHCARE · Cap: $1.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 50477% more annual revenue ($606.42M vs $1.20M). OCS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
OCS
Avoid29
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 136.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : OCS
The strongest argument for OCS centers on Revenue Growth, Debt/Equity. Revenue growth of 136.0% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : OCS
The primary concerns for OCS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while OCS is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
OCS is growing revenue faster at 136.0% — sustainability is the question.
OCS generates stronger free cash flow (-16M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Oculis Holding AG Ordinary shares
HEALTHCARE · BIOTECHNOLOGY · USA
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?